The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib

详细信息    查看全文

• 作者：Francesco Grossi (1) francesco.grossi@istge.it
  Erika Rijavec (1)
  Maria Giovanna Dal Bello (1)
  Carlotta Defferrari (1)
  Annalisa Brianti (1)
  Giulia Barletta (1)
  Carlo Genova (1)
  Carmelina Murolo (2)
  Maurizio Cosso (2)
  Gabriella Fontanini (3)
  Laura Boldrini (3)
  Mauro Truini (4)
  Paolo Pronzato (5)
• 关键词：Non ; small ; cell lung cancer – ; Gefitinib – ; Erlotinib – ; EGFR ; TKI toxicity – ; EGFR mutation – ; K ; ras mutation
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2012
• 出版时间：June 2012
• 年：2012
• 卷：69
• 期：6
• 页码：1407-1412
• 全文大小：175.9 KB
• 参考文献：1. J盲nne PA, Engelman JA, Johnson BE (2005) Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23:3227–3234
  2. Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445–2459
  3. Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537
  4. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957
  5. Lee JS, Park K, Kim SW et al (2009) A randomised phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. World Conference on Lung Cancer Proceedings 2009:PRS 4
  6. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128
  7. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388
  8. Shepherd FA, Rodrigues Pereira J et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132
  9. Bezjak A, Tu D, Seymour L et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24:3831–3837
  10. Zhou C, Wu Y, Chen G et al (2010) Efficacy results from the randomise phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in Chinese advanced non-small-cell lung cancer patients with EGFR activating mutations (abstract # LBA13). Ann Oncol 21 (Suppl 8):viii6
  11. Rosell R, Gervais R, Vergnenegre A et al (2011) Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. In: ASCO Annual Meeting Proceedings. Part I. vol 29, No. 15 (May 20 Suppl):7503
  12. Togashi Y, Masago K, Fujita S et al (2011) Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer 74(1):98–102
  13. Baselga J, Rischin D, Ranson M et al (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, inpatients with five selected solid tumor types. J Clin Oncol 20:4292–4302
  14. Hidalgo M, Siu LL, Nemunaitis J et al (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267–3279
  15. Cho BC, Im CK, Park MS et al (2007) Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 25:2528–2533
  16. Vasile E, Tibaldi C, Chella A et al (2008) Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. J Thorac Oncol 3:912–914
  17. Lee DH, Kim SW, Suh C et al (2008) Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 19:2039–2042
  18. Wong AS, Soong R, Seah SB et al (2008) Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 3:400–404
  19. Sim SH, Han SW, Oh DY et al (2009) Erlotinib after gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. Lung Cancer 65:204–207
  20. Costa DB, Son K, Cho BC et al (2008) Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 14:7060–7067
  21. Zhou ZT, Xu XH, Wei Q et al (2009) Erlotinib in advanced non-small-cell lung cancer after gefitinib failure. Cancer Chemother Pharmacol 64:1123–1127
  22. Katayama T, Shimizu J, Suda K et al (2009) Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4:1415–1419
  23. Wong MK, Lo AI, Lam B et al (2010) Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 65:1023–1028
  24. Asami K, Kawahara M, Atagi S et al (2011) Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. Lung Cancer 73:211–216
  25. Hata A, Katakami N, Yoshioka H et al (2011) Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection. Lung Cancer 74(2):268–273
  26. Shih YN, Liou JL, Jiang WC et al (2007) Phase II study of erlotinib in patients with advanced non-small cell lung cancer who failed prior gefitinib treatment. J Thorac Oncol 8:S743 (P3–P150)
  27. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
  28. Choong NW, Dietrich S, Seiwert TY et al (2006) Gefitinib response of erlotinib-refractory lung cancer involving meninges–role of EGFR mutation. Nat Clin Pract Oncol 3:50–57
  29. Kaira K, Naito T, Takahashi T et al (2010) Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer 68:99–104
  30. Guo R, Chen X, Wang T et al (2011) Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer 11:90
  31. Watanabe S, Tanaka J, Ota T et al (2011) Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer 11:1
  32. Chou WC, Huang SF, Yeh KY et al (2006) Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes. Jpn J Clin Oncol 36:523–526
  33. Riely GJ, Kris MG, Zhao B et al (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150–5155
• 作者单位：1. S.S. Tumori Polmonari, Istituto Nazionale per la Ricerca sul Cancro, L.go Benzi, 10, 16132 Genoa, Italy2. S.C. Diagnostica per immagini ed interventistica oncologica, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy3. Sezione Anatomia Patologica, Dipartimento di Chirurgia Universit脿 di Pisa, Pisa, Italy4. S.C. Anatomia e Citoistologia patologica, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy5. S.C. Oncologia Medica A, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Pharmacology and Toxicology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0843

文摘

Purpose Recent studies have demonstrated that erlotinib therapy may be considered an option for patients with advanced non-small-cell lung cancer who experienced disease progression after treatment with gefitinib, particularly in patients in whom the disease had been stabilized for a long time prior to gefitinib therapy. The aim of this study was to evaluate the disease control rate and toxicity of gefitinib in patients whose disease progressed after erlotinib therapy.